AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03470454 — intervention group
Intervention type: DRUG
Intervention: Linagliptin Oral Tablet
Description: Linagliptin for blood glucose control
Study NCT06787027 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage technique
Description: Following the morning surgery, manual lymphatic drainage therapy was administered in the afternoon of the same day by a professional physiotherapist.
Study NCT06787027 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Treatment group
Description: patients were prescribed antibiotics (amoxicillin with clavulanic acid, 1 g, twice daily), analgesics (paracetamol, 500 mg, twice daily), and mouthwash (chlorhexidine gluconate, three times daily) for five days. Cold application was recommended to all patients.
Study NCT01853748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Study NCT01853748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study NCT01853748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab emtansine
Study NCT01663857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2228820
Description: Administered Orally
Study NCT01663857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered IV
Study NCT01663857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Administered IV
Study NCT01663857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered Orally
Study NCT01663857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV
Study NCT01663857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Administered IV
Study NCT04835883 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CS20AT04 (allogenic bone marrow derived mesenchymal stem cell)
Description: Two intravenous infusions of CS20AT04 (2.0×10\^6cell/kg), on 0 day and on 12 weeks The target population of this study is subjects in South Korea with a diagnosis of either lupus nephritis or lupus cytopenia.
Study NCT02329782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Readiness Program
Description: The ARP consists of pre-treatment (including practice trials to determine readiness for and timing of ART initiation), early-treatment, and ongoing maintenance training (using a performance-based, dose regulation mechanism to tailor the amount and intensity) phases
Study NCT03151083 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based Self-help Insomnia Intervention
Description: The investigators will use the program, SHUTiTM for the treatment of insomnia. The intervention is a CBT-based 6-week, self-administered course accessed via the Internet on mobile, desk-top, and other devices. The program is split into six modules, completed weekly, which include instruction on psycho-education, stimulus control, relaxation training, sleep restriction, medication tapering, and addressing cognitive distortions. The content is delivered via text, video vignettes, case histories, interactive learning tools, interactive skills assessments, symptom assessments, and a sleep log. Homework is assigned after each module. Providers and support staff can follow treatment progress via access to a dashboard of patient information collected by the program. Such information includes progress through the modules, date of last engagement, symptom assessment outcomes, and sleep log data abstracted into commonly used sleep indices such as sleep onset latency and sleep efficiency.
Study NCT03151083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Self-help Insomnia Intervention
Description: The investigators will use the program, SHUTiTM for the treatment of insomnia. The intervention is a CBT-based 6-week, self-administered course accessed via the Internet on mobile, desk-top, and other devices. The program is split into six modules, completed weekly, which include instruction on psycho-education, stimulus control, relaxation training, sleep restriction, medication tapering, and addressing cognitive distortions. The content is delivered via text, video vignettes, case histories, interactive learning tools, interactive skills assessments, symptom assessments, and a sleep log. Homework is assigned after each module. Providers and support staff can follow treatment progress via access to a dashboard of patient information collected by the program. Such information includes progress through the modules, date of last engagement, symptom assessment outcomes, and sleep log data abstracted into commonly used sleep indices such as sleep onset latency and sleep efficiency.
Study NCT00623298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy
Study NCT00623298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group IPT
Study NCT00623298 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: 6 months-baseline
Study NCT00063336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: A computerized cognitive rehabilitation treatment with day-program activities
Study NCT00063336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-skills training
Description: A computerized cognitive rehabilitation treatment with day-program activities
Study NCT01619098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Navigator
Description: In addition to usual care, the intervention adds the services of a community health worker, the Patient Navigator (PN), for study patients. The PN participates in bedside meetings, facilitates communication between the patient and the primary care team, conducts weekly outreach phone calls to further address patient needs, and makes reminder calls prior to all medical appointments to facilitate timely outpatient follow-up.
Study NCT01619098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care includes provision of a Home Care Plan (HCP) to patients at discharge, and electronic transmission of HCP to PCP with telephone follow-up by primary care RN
Study NCT06462742 — intervention group
Intervention type: PROCEDURE
Intervention: Microwave ablation (MWA) versus Liver Resection (LR)
Description: Microwave ablation (MWA) is one of the newer modality of thermal ablation and has proven its safety and efficacy in the management of the tumors amenable for ablation for primary and metastatic diseases.~Liver resection is a surgery to remove part of the liver to eradicate tumors.
Study NCT02500719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computational Model - Real-time Support Vector Machine
Description: A support vector machine algorithm will be applied in real-time to fMRI data to identify distributed patterns of co-activated brain regions that specifically encode high emotional arousal (i.e,. high SCR) to the stress/trauma memory (note, this is equivalent to predictions of fitted Q-iteration in which the all actions are specified as zero, reward is equal to the support vector machine predicted arousal, and the discount factor of 0). The resulting idiosyncratic brain map would inform the neurofeedback phase in the next stage of fMRI data collection. This approach will first be piloted in the healthy participant group, then implemented in the PTSD participant group.
Study NCT03955809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 0.5
Description: İntrarticular Ketamine 0.5 mg/kg + 0.9 Nacl Total Volume 20 ml
Study NCT03955809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 1
Description: İntrarticular Ketamine 1 mg/kg + 0.9 NaCl Total Volume 20 ml
Study NCT03955809 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: % 0.9 NaCl
Description: Intraarticular %0.9 NaCl
Study NCT00634296 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle added by aerobic to aerobic alone
Description: Inspiratory muscle added by aerobic to aerobic alone
Study NCT01015105 — intervention group
Intervention type: OTHER
Intervention: observation
Description: observation
Study NCT01344759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of dexmedetomidine 1 mcg/kg will be administered over 10 minutes followed by a continuous infusion of dexmedetomidine at rate of 1 mcg/kg/h using a syringe pump.
Study NCT01344759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of propofol 2 mg/kg will be administered over 2 minutes followed by a continuous infusion of propofol at rate of 100 mcg/kg/minute using a syringe pump.
Study NCT01212146 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei IMPC 2.1 LMGP22043
Description: participants will complement their usual lifestyles and dietary intakes with probiotic artichokes, enriched with the probiotic strain Lactobacillus paracasei IMPC2.1 (LMGP22043). The product contains approximately 1.20 x 10\^8 CFU of live probiotic cells of Lactobacillus paracasei IMPC 2.1 LMGP22043 per gramme, which resulted in a daily dose of about 2 x 10\^10 CFU.
Study NCT01212146 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ordinary artichokes
Description: Probiotic artichokes will be tested against ordinary artichokes (probiotic free) of identical shape, texture, and appearance produced by the same manufacturer. Artichokes will be put in similar packages and there will be no way to distinguish between the two products.
Study NCT02542137 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin for metastatic lesions of small cell lung cancer.
Study NCT02542137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymalfasin
Description: Patients with metastatic lesions of small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin ( given twice a week with an interval of 3-4 days each week).
Study NCT00591929 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Passive Motion
Description: at least 48 hours of continuous passive motion following ORIF of fractures around the knee
Study NCT00565201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox and rehab
Description: Patients will BOTOX® (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
Study NCT00565201 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and rehab
Description: Patients will receive placebo saline (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
Study NCT01856998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Study NCT01856998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diprivan
Study NCT00458861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG9924
Description: Subcutaneous administration of BG9924 given every other week for 12 weeks
Study NCT00458861 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Subcutaneous administration of placebo given every other week for 12 weeks
Study NCT03389880 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Description: A surgical procedure in which parts of the knee joint are replaced with artificial parts (prostheses)
Study NCT03389880 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty
Description: A surgical procedure in which parts of the knee joint are replaced with artificial parts (prostheses)
Study NCT03389880 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patellar denervation
Description: circumpatellar electrocautery with monopolar coagulation diathermy
Study NCT00488137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 2 mg o.d.
Study NCT00488137 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: o.d.
Study NCT00488137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 4 mg o.d.
Study NCT02834078 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BGG
Study NCT02834078 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03971916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM9161(HL161BKN)
Description: Subcutaneous injection; Single dose on Day 1
Study NCT03971916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection; Single dose on Day 1
Study NCT02512172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral CC-486
Study NCT02512172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Study NCT02512172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Study NCT04542876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guduchi Ghan Vati
Description: Guduchi Ghan Vati was orally administered 2 tablets (1000 mg) twice daily for 2 weeks.
Study NCT02032615 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Education plus Gudness Nutritional Bar
Study NCT02032615 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education
Study NCT04433923 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy with aluminum foil
Study NCT04433923 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Phototherapy without aluminum foil
Study NCT00545935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylenblue-Amodiaquine (MB-AQ)
Description: For 3 days twice daily 10 mg/kg MB accompanied by once daily 10 mg/kg AQ
Study NCT00545935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylenblue-Artesunate (MB-AS)
Description: 3 days once daily 4 mg/kg AS accompanied by twice daily 10 mg/kg MB given over 7 days
Study NCT00545935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate-Amodiaquine (AS-AQ)
Description: For 3 days once daily 10 mg/kg AQ accompanied by 4mg/kg AS.
Study NCT03175315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment and education program for patients with diabetes who use flash glucose monitoring (FLASH)
Description: Treatment and education program based on the self-management theory of behavioral medicine. The program is delivered by certified and specially trained diabetes educators.
Study NCT03324477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hypertonic saline 3%
Description: hypertonic saline 3% is a type of crystalloid solutions with osmolarity higher than that of plasma
Study NCT04290000 — intervention group
Intervention type: OTHER
Intervention: additional biological samples during CAR-T CELL treatment
Description: Blood samples (additional tubes) and marrow (quantity taken in addition from the same aspiration) will be collected in addition to those useful for the follow up of the patients (progress of their disease after treatment with CAR-T Cells) at specific points in his treatment journey.~The following samples will also be collected during Apheresis and at Car-T Cells reinjection :~* Apheresis sampling~* CAR-T Cells collected from bag rinsate~In case of invasion, a skin biopsy will be made, 2 days and 8 days after the beginning of the CAR T Cell Treatment, during the patient's hospitalization and during a consultation visit in case of therapeutic progression or failure.
Study NCT01399385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR Imaging Techniques - 1
Description: Group 1 will consist of subjects with a 10-year total CHD risk \<10% (low)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
Study NCT01399385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR Imaging Techniques - 2
Description: Group 2 will consist of subjects with a 10-year total CHD risk 10-20% (intermediate)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
Study NCT01399385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR Imaging Techniques - 3
Description: Group 3 will consist of subjects with a 10-year total CHD risk >20% (high)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
Study NCT01399385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR Imaging Techniques - 4
Description: Group 4 no known risk factors (control subjects)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
Study NCT03624712 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: uterine neoplasms
Description: Analysis of circulating (CTC) and disseminating tumor cells (DTC), determination of Human Papilloma Virus (HPV), Douglas cytology, DNA analysis in blood, proteome analysis, sentinel lymph node detection
Study NCT02827175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample
Study NCT02016911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg
Study NCT02016911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: semaglutide
Description: Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg
Study NCT03809234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron 8mg with Saline & Tariquidar
Description: Each participant will receive two IV infusions of ondansetron, 24 hours apart. In the first and second sessions, respectively, placebo (D5W) or tariquidar (4mg/kg dose in D5W) 22 will be administered IV over 60 minutes. Ondansetron will be diluted in 50mL 0.9% normal saline, and tariquidar will be diluted in 250mL D5W.
Study NCT03809234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8mg with Saline & Tariquidar
Description: Each participant will receive two IV infusions of ondansetron, 24 hours apart. In the first and second sessions, respectively, placebo (D5W) or tariquidar (4mg/kg dose in D5W) 22 will be administered IV over 60 minutes. Ondansetron will be diluted in 50mL 0.9% normal saline, and tariquidar will be diluted in 250mL D5W.
Study NCT03809234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron 16mg with Saline & Tariquidar
Description: Each participant will receive two IV infusions of ondansetron, 24 hours apart. In the first and second sessions, respectively, placebo (D5W) or tariquidar (4mg/kg dose in D5W) 22 will be administered IV over 60 minutes. Ondansetron will be diluted in 50mL 0.9% normal saline, and tariquidar will be diluted in 250mL D5W.
Study NCT03809234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 16mg with Saline & Tariquidar
Description: Each participant will receive two IV infusions of ondansetron, 24 hours apart. In the first and second sessions, respectively, placebo (D5W) or tariquidar (4mg/kg dose in D5W) 22 will be administered IV over 60 minutes. Ondansetron will be diluted in 50mL 0.9% normal saline, and tariquidar will be diluted in 250mL D5W.
Study NCT04481763 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Camrelizumab
Description: Camrelizumab is 200 mg iv. administered every 2 weeks for 3 cycles with radiotherapy ( 50gy, 25 times for 5weeks)
Study NCT04481763 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: radiotherapy
Description: radiotherapy
Study NCT01863719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistimethate sodium
Description: Aerosol: In Dosing period 2 subjects receive 75mg colistin base activity via aerosol every 6 hours x 4 doses, followed by a washout period of at least 3 days. In Dosing period 3 subjects receive 75mg colistin base activity via aerosol every 6 hours x 4 doses in combination with 3.3mg/kg colistin base activity IV every 8 hours x 3 doses.
Study NCT01863719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistimethate sodium
Description: Intravenous: In Dosing period 1 subjects receive 3.3mg/kg colistin base activity every 8 hours x 3 doses (total exposure 10mg/kg) intravenously (IV) followed by a washout period of at least 3 days. In Dosing period 3 subjects receive 3.3mg/kg colistin base activity IV every 8 hours x 3 doses in combination with 75mg colistin base activity via aerosol every 6 hours x 4 doses.